Rahman M R, Sheikh S H, Lima I J, Islam M R, Faisal M, Islam M S, Faruk M O, Jalal M T
Dr Md Rayhanur Rahman, Assistant Professor, Department of Surgery, Pabna Medical College, Pabna, Bangladesh.
Mymensingh Med J. 2016 Jan;25(1):61-5.
Carcinoembryonic antigen (CEA) is well established tumor marker for colorectal cancers worldwide. Recent studies show that serum prolactin level is also raised in colorectal cancers. The purpose of the study is to evaluate the correlation of serum CEA and Prolactin with Dukes' staging of colorectal carcinomas. Between January 2013 and June 2013, Serum CEA and Serum Prolactin were measured by radioimmunoassay from 103 patients who were histopathologically diagnosed as colorectal carcinomas. Evaluation of the stages of the colorectal cancers was done on the basis of preoperative investigations and postoperative histopathology and correlated with Preoperative Serum CEA and Serum Prolactin. Results were presented as median value, range and percentage. Male to female ratio was 1.4:1 with median age of 42.26 years (range 17-78 years). Most of the patients in this series presented with carcinoma rectum (42%). Most of the patients (52%) were found in Dukes' stage C and 27% and 15% cases were found as Dukes' stage B and Dukes' stage D respectively. Stage of the disease is directly proportionate to percentage of the patient with high serum prolactin except early stage (Dukes' A-50%, Dukes' B-28.6%, Dukes' C-33.3% & Dukes' D-46.7%). Similarly serum CEA level is directly proportionate to tumor stage (Dukes' A-0%, Dukes' B-32%, Dukes' C-40.7% & Dukes' D-74.7%). A preoperative high serum CEA value suggests advanced disease either locally or with distant metastasis. In contrast preoperative high serum prolactin (hyperprolactinaemia) did not suggest advanced disease as it can be elevated even in early stage of disease. Serum CEA and Serum Prolactin both are valuable tumor markers but serum CEA could not be replaced by serum Prolactin. Serum Prolactin may be a helpful marker in earlier stages of the colorectal cancer.
癌胚抗原(CEA)是全球范围内公认的结直肠癌肿瘤标志物。最近的研究表明,结直肠癌患者的血清催乳素水平也会升高。本研究的目的是评估血清CEA和催乳素与结直肠癌Dukes分期之间的相关性。在2013年1月至2013年6月期间,采用放射免疫分析法对103例经组织病理学诊断为结直肠癌的患者测定血清CEA和血清催乳素。根据术前检查和术后组织病理学对结直肠癌分期进行评估,并与术前血清CEA和血清催乳素进行相关性分析。结果以中位数、范围和百分比表示。男女比例为1.4:1,中位年龄为42.26岁(范围17 - 78岁)。本系列中大多数患者为直肠癌(42%)。大多数患者(52%)处于Dukes C期,27%和15%的病例分别为Dukes B期和Dukes D期。疾病分期与高血清催乳素患者的百分比直接成正比,但早期(Dukes A期 - 50%,Dukes B期 - 28.6%,Dukes C期 - 33.3%,Dukes D期 - 46.7%)除外。同样,血清CEA水平与肿瘤分期直接成正比(Dukes A期 - 0%,Dukes B期 - 32%,Dukes C期 - 40.7%,Dukes D期 - 74.7%)。术前血清CEA值高提示疾病局部进展或有远处转移。相比之下,术前高血清催乳素(高催乳素血症)并不提示疾病进展,因为即使在疾病早期其水平也可能升高。血清CEA和血清催乳素都是有价值的肿瘤标志物,但血清催乳素不能替代血清CEA。血清催乳素可能是结直肠癌早期阶段的一个有用标志物。